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Objective. Aberrant activation of Wnt signaling has been observed in tissues from patients with systemic sclerosis (SSc). This study aimed to determine the role of transforming growth factor b (TGFb) in driving the increased Wnt signaling, through modulation of axis inhibition protein 2 (Axin-2), a critical regulator of the Wnt canonical pathway.
Methods. Canonical Wnt signaling activation was analyzed by TOPflash T cell factor/lymphoid enhancer factor promoter assays. Axin-2 was evaluated in vitro by analysis of Axin-2 primary/mature transcript expression and decay, TGFb receptor type I (TGFbRI) blockade, small interfering RNA-mediated depletion of tristetraprolin 1, and XAV-939-mediated Axin-2 stabilization. In vivo, Axin-2 messenger RNA (mRNA) and protein expression was determined in skin and lung biopsy samples from mice that express a kinase-deficient TGFbRII specifically on fibroblasts (TbRIIDk-fib-transgenic mice) and from littermate controls.
Results. SSc fibroblasts displayed an increased response to canonical Wnt ligands despite basal levels of Wnt signaling that were comparable to those in healthy control fibroblasts in vitro. Notably, we showed that SSc fibroblasts had reduced basal expression of Axin-2, which was caused by an endogenous TGFb-dependent increase in Axin-2 mRNA decay. Accordingly, we observed that TGFb decreased Axin-2 expression both in vitro in healthy control fibroblasts and in vivo in TbRIIDk-fib-transgenic mice. Additionally, using Axin-2 gain-and loss-of-function experiments, we demonstrated that the TGFb-induced increased response to Wnt activation characteristic of SSc fibroblasts depended on reduced bioavailability of Axin-2.
Conclusion. This study highlights the importance of reduced bioavailability of Axin-2 in mediating the increased canonical Wnt response observed in SSc fibroblasts. This novel mechanism extends our understanding of the processes involved in Wnt/b-catenin-driven pathology and supports the rationale for targeting the TGFb pathway to regulate the aberrant Wnt signaling observed during fibrosis.
Tissue fibroblasts are the key cellular elements of fibrosis, and are primarily involved in regulating extracellular matrix (ECM) homeostasis. Dysregulated fibroblast activation can result in the excessive synthesis and deposition of collagens and other ECM proteins within tissues, leading to organ dysfunction and failure (1, 2) . Sustained transforming growth factor b (TGFb) activity has been shown to be a central mediator of fibroblast activation and can reproduce many of the hallmarks associated with fibrosis both in vitro and in vivo (3) (4) (5) (6) . Indeed, TGFb-treated fibroblasts display a gene expression profile similar to that of dermal fibroblasts from patients with diffuse cutaneous systemic sclerosis (dcSSc) (7) .
The TbRIIDk-fib-transgenic mouse model, characterized by constitutive TGFb signaling through Col1a2-mediated fibroblast-specific expression of a kinase-deficient TGFb receptor type II (TGFbRII), replicates key constitutive features of SSc, including dermal fibrosis as well as susceptibility to other organ-based complications, such as lung fibrosis and pulmonary hypertension (8) . This model has proven to be valuable for the delineation of profibrotic pathways and especially for investigating cross-talk between TGFb and other relevant mediators (9) .
Recently, several studies have shown that canonical Wnt signaling is activated during fibrosis in SSc and in other fibrotic conditions (10) (11) (12) (13) (14) . Indeed, this activation may have an important role in the initiation/ maintenance of fibrosis; however, the biochemical and biophysical mechanisms of this activation are yet to be identified, and the relative contribution of cross-talk to TGFb pathway activation is unclear.
Canonical Wnt signaling is dependent on b-catenin bioavailability, which is regulated by the b-catenin destruction complex. This complex is primarily composed of axis inhibition protein (Axin), adenomatous polyposis coli, casein kinase 1, and glycogen synthase kinase 3b (GSK-3b), which together facilitate the phosphorylation and subsequent ubiquitin-mediated degradation of b-catenin (15) . Canonical Wnt agonist activation of this pathway recruits the destruction complex to the plasma membrane, thereby lowering its capacity to induce b-catenin proteasomal degradation (16) . As a result, increased levels of free cytosolic b-catenin can undergo nuclear translocation, leading to the up-regulation of canonical Wnt target genes through b-catenin-mediated activation of the T cell factor (TCF)/ lymphoid enhancer factor (LEF) transcription factors.
Specifically, Axin-2 and Axin-1 are essential scaffold proteins for the formation of the b-catenin destruction complex and therefore act as negative regulators of Wnt signaling (17) (18) (19) . While the gene for Axin-1 is constitutively expressed, the gene for Axin-2 is a direct transcriptional target of canonical Wnt signaling, acting as part of a negative feedback system to control Wnt signaling activation (20, 21) .
Axin-2 À/À mice are viable, and delivery of Axin-2 complementary DNA (cDNA) can rescue the lethal Axin-1 À/À phenotype (22, 23) . Uniquely, heterozygous Axin-2 germline mutations in humans can lead to familial tooth agenesis (24) . Interestingly, in the chondrocyte lineage, TGFb promotes b-catenin accumulation while inhibiting the expression of Axin-1 and Axin-2, thus providing a contextspecific example of the interplay between these pathways (25) . Recently, the endogenous Wnt antagonist, Dkk-1, has been described to be TGFb responsive with transgenic expression attenuating experimental fibrosis (26) . Our study aimed to determine whether increased TGFb signaling could play a role in the observed canonical Wnt signaling hyperactivation of tissue fibroblasts during SSc.
PATIENTS AND METHODS
Reagents. Adult human dermal fibroblasts were obtained from 5 patients with early dcSSc and 5 healthy controls and cultured (PromoCell) (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40437/abstract). Primary cells were immortalized using human telomerase reverse transcriptase (hTERT) to make healthy control hTERT and SSc hTERT. Briefly, hTERT pBABE (Neo) (a kind gift from Prof. M. A. Knowles, University of Leeds, Leeds, UK) was transfected into Phoenix amphotropic retroviral packaging cells using TransIT-293 (Mirus Bio), and virus supernatant containing 8 lg/ml Polybrene was added to primary cells and selected with 1,000 lg/ml G418 48 hours after transduction. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich) containing 10% fetal calf serum (FCS; Biosera) and incubated at 37°C under 5% CO 2 . All experiments conducted with hTERT fibroblasts were validated with primary (not immortalized) fibroblasts. Primary fibroblasts were used between passages 2 and 5. Starvation was performed with 0.5% serum DMEM, and stimulations were performed with recombinant human TGFb (5 ng/ml; Sigma-Aldrich) or recombinant human Wnt-3a (100 ng/ml; R&D Systems). The messenger RNA (mRNA) decay rate was investigated using actinomycin D (5 lg/ml; Sigma-Aldrich). Axin stabilization was achieved using XAV-939 Tankyrase 1/2 Inhibitor (1 lM; Calbiochem), and TGFb signaling was inhibited using SD-208 TbRI Kinase Inhibitor (1 lM; Sigma-Aldrich).
Study approval. Informed consent was obtained from all patients, and studies were granted approval by the Leeds Teaching Hospitals NHS Trust Medical Ethics Committee (Leeds Teaching Hospital Research Ethics Committee approval no. 10/ H1306/88). All scleroderma patients fulfilled the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria for SSc (27) and were classified as having dcSSc according to the LeRoy and Medsger criteria (28) .
TbRIIDk-fib-transgenic mice. The generation of TbRIIDkfib-transgenic mice has been described previously (8) . Constitutive TGFb signaling is mediated by fibroblast-specific expression of kinase-deficient TGFbRII. Dermal and lung tissues were obtained from 6-8-week-old age-matched transgenic and wild-type (WT) littermates, and each experiment was performed on at least 5 mice for each condition. Animals were housed in a clean conventional colony, with access to food and water ad libitum. Strict adherence to institutional guidelines was practiced, and full local ethics committee and Home Office approvals were obtained.
Histology studies. Formalin-fixed skin specimens were embedded in paraffin and sections were cut at 5 lm. Skin fibrosis was evaluated by measuring the thickness between the dermal-epidermal boundary and the dermal-subcutaneous fat boundary and further evaluated using Masson's trichrome blue staining. Antigen retrieval was performed using 10 mM sodium citrate (pH 6.0), and sections were stained with anti-Axin-2 antibody (Sigma-Aldrich) followed by staining with StreptABComplex/HRP (DakoCytomation) and visualized with 3,3 0 -diaminobenzidine tetrahydrochloride (Vector). Microscopic analysis was performed using an Olympus BX50 with MicroFire (Optronics), and images were captured at 209 magnification using Stereo Investigator software (MBF Bioscience).
Cell lysate preparation. Cells were lysed in radioimmunoprecipitation assay buffer (Sigma-Aldrich) supplemented with complete protease and phosphatase inhibitor cocktails (Roche). Whole cell lysate protein concentration was then quantified using a bicinchoninic acid (BCA) colorimetric protein assay kit in accordance with the protocol of the manufacturer (Thermo Fisher).
Western blotting. Cell lysates were electrophoresed on a 4-12% Bis-Tris gradient gel using a NuPAGE gel system and transferred onto an Immobilon-P PVDF membrane (EMD Millipore). The membranes were blocked with 5% milk in Tris buffered saline-0.1% Tween 20 and incubated with anti-Axin-2 (New England Biolabs), anti-Axin-1 (New England Biolabs), and anti-a-smooth muscle actin (anti-a-SMA; Abcam). Incubation with the appropriate horseradish peroxidase-conjugated secondary antibody allowed for chemiluminescence detection using enhanced chemiluminescence reagent (GE Healthcare). Equal loading of proteins was achieved using a BCA protein assay kit and confirmed by visualization of GAPDH (Abcam).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Total cellular RNA extraction and purification were performed using an RNeasy kit (Qiagen), and cDNA was prepared using a SuperScript II first-strand cDNA synthesis kit (Life Technologies) in accordance with manufacturer protocols. Gene expression was quantified by SYBR Green RT-PCR on an ABI Prism 7700 Sequence Detection System (Life Technologies). . Increased response to canonical Wnt signaling and decreased expression of axis inhibition protein 2 (Axin-2) in fibroblasts from patients with systemic sclerosis (SSc). A, b-catenin-dependent TOPflash (Tcell factor/lymphoid enhancer factor) reporter activity in healthy control (HC) and SSc dermal fibroblasts 24 hours after treatment with 100 ng/ml recombinant human Wnt-3a. B and C, Expression of mRNA for the canonical Wnt target Axin-2 in healthy control and SSc dermal fibroblasts 24 hours after treatment with 100 ng/ml recombinant human Wnt-3a (B) or 5 ng/ml transforming growth factor b (TGFb) (C), quantified by quantitative reverse transcriptase-polymerase chain reaction. Data were normalized to 18S ribosomal RNA, and values displayed are relative to those in untreated healthy controls. D, Axin-2 protein expression determined by Western blot analysis under the same conditions as in C. Values are the mean AE SEM (n = 5 experiments). ** = P < 0.01; **** = P < 0.001 by Mann-Whitney U test. a-SMA = a-smooth muscle actin.
we used 5 0 -AGCCTAAAGGTCTTATGTGG-3 0 (forward), 5 0 -ATGGAATCGTCGGTCAGT-3 0 (reverse), and the 18S rRNA primers shown above. Amplifications were analyzed with SDS software, version 2.3 (Life Technologies) and normalized to 18S rRNA using the DDC t method.
TOPflash reporter assay. The TOPflash/FOPflash luciferase reporter system (a kind gift from Prof. Randall Moon, University of Washington, Seattle) measured b-catenin-driven TCF/LEF transcriptional activation. Fibroblasts were transfected with the TOPflash construct at a concentration of 1 lg/ ml per well in a 12-well plate using Lipofectamine 2000 transfection reagent (Life Technologies). For transfection efficiency normalization, cells were cotransfected with a pCMV-Renilla luciferase vector at a concentration of 100 ng/ml. Transfection complexes were removed after 2 hours, and cells were stimulated with Wnt-3a in DMEM/0.5% FCS for 24 hours. Cell lysates were prepared, and luciferase activity was evaluated using a dual luciferase reporter system in accordance with the protocol of the manufacturer (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity and expressed as the relative fold change.
Small interfering RNA (siRNA)-mediated gene silencing. Cells were seeded to reach a confluence of 70% on the day of transfection in DMEM/10% FCS. On the day of transfection, cell medium was changed to DMEM/5% FCS. Silencer Select, predesigned, nontargeting (scrambled) siRNA (AM4611), Axin-2 siRNA (S15818), and tristetraprolin 1 (TTP-1) siRNA (s14978) (Life Technologies) were transfected using N-TER transfection reagent (Sigma-Aldrich). Transfection complexes were added to fibroblasts at a final siRNA concentration of 10 nM and removed after 24 hours. Gene silencing was monitored for 24-96 hours posttransfection at the mRNA and protein levels.
Statistical analysis. Statistical analyses were performed using the nonparametric Mann-Whitney U test for unpaired samples. Experimental data are presented as the mean AE SEM. P values less than or equal to 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism software, version 5.0.
RESULTS
Increased canonical Wnt signaling responsiveness displayed by SSc fibroblasts. To measure the activation of the canonical Wnt signaling pathway in explanted dermal fibroblasts from SSc patients and healthy controls, b-catenin-mediated TCF/LEF transcription was quantified by TOPflash reporter activity. Compared to healthy control fibroblasts, no increase in basal level TOPflash activity was observed in SSc fibroblasts. However, following 24 hours of treatment with canonical Wnt-3a ligand, SSc fibroblasts displayed a 9.9-fold increase in reporter activity compared to a 4.8-fold increase observed in healthy control fibroblasts (P < 0.01) ( Figure 1A ). Consistent with these findings, Wnt-3a induced expression of mRNA for Axin-2 5.0-fold in SSc fibroblasts relative to basal levels, compared to a 1.8-fold increase in healthy control fibroblasts (P < 0.001) ( Figure 1B) .
Interestingly, we found that basal expression of mRNA for Axin-2 was reduced by 52% in SSc fibroblasts ( Figure 1B ). Since Axin-2 plays an essential role in regulating the activity of the Wnt signaling pathway, we set out to evaluate the regulatory effects of TGFb on expression of mRNA for Axin-2. Stimulation of healthy control fibroblasts with TGFb for 24 hours reduced expression of mRNA for Axin-2 to 49% at 24 hours (P < 0.001), which was analogous to the basal levels of expression observed in SSc fibroblasts (i.e., 52% of basal levels in healthy control fibroblasts) ( Figure 1C) . Additionally, TGFb treatment of SSc fibroblasts further reduced expression of mRNA for Axin-2 to 20% of basal levels in healthy control fibroblasts (P < 0.01) ( Figure 1C) . Consistently, Axin-2 protein expression in healthy control fibroblasts treated with TGFb was comparable to the level observed in SSc fibroblasts ( Figure 1D) .
Constitutive TGFb activation leads to tissue fibrosis and reduced Axin-2 expression in TbRIIDk-fib-transgenic mice. The TbRIIDk-fib-transgenic mouse model of SSc was used to validate the effects of TGFb signaling on Axin-2 expression in vivo. Consistent with reported data, TbRIIDk-fib-transgenic mice developed a significant dermal fibrosis characterized by increased dermal thickness, collagen deposition, and loss of subcutaneous fat compared to WT controls (8, 29) (Figure 2A ). Immunohistochemistry studies determined that dermal tissue from these mice had an overall reduction in Axin-2 expression ( Figures 2B and  C) , which was evident in both the epidermal and dermal compartments. Accordingly, in transgenic mouse skin, expression of mRNA for Axin-2 was reduced by 65% compared to that in WTcontrol mouse skin (P < 0.05) (see Supplementary Figure 1A , http://onlinelibrary.wiley.com/doi/ 10.1002/art.40437/abstract). Furthermore, Axin-2 protein expression was also reduced in lung tissue from transgenic mice, particularly in areas where the normal architecture was lost ( Figure 2D ).
TGFb priming of fibroblasts reproduces the increased canonical Wnt signaling amplitude observed in SSc fibroblasts through Axin-2 down-regulation. To determine whether the TGFb-mediated decrease in Axin-2 expression could be responsible for the increased sensitivity of fibroblasts to canonical Wnt ligands, we performed 24-hour sequential stimulation experiments. TGFb-primed healthy control fibroblasts showed a 9.8-fold increase in TOPflash activation in response to Wnt-3a, compared to the 4.8-fold increase in cells not previously treated with TGFb (P < 0.001) ( Figure 3A) . The increased response to Wnt was observable as early as 2 hours following TGFb stimulation and persisted for up to 72 hours (see Supplementary Figure 1B , http://onlinelibrary.wiley.com/doi/10. 1002/art.40437/abstract). Importantly, fibroblasts treated with TGFb alone did not show any increase of TOPflash activity ( Figure 3A) . 
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GILLESPIE ET AL Next, we set out to determine the mechanism by which TGFb regulates Axin-2 expression in fibroblasts. TGFb induced a significant and time-dependent reduction in expression of mRNA for Axin-2 that was observable within 30 minutes, and this persisted for up to 72 hours (P < 0.01) (Figures 3B and C) . Similarly, Axin-2 protein expression was decreased within 2 hours, and the decrease continued up to 72 hours ( Figures 3B and C) . In Figure 3 . TGFb priming of fibroblasts reproduces the increased canonical Wnt signaling amplitude observed in SSc fibroblasts through posttranscriptional regulation of Axin-2 expression. A, Results of assay for TOPflash activity in healthy control fibroblasts incubated in media alone or primed for 24 hours with 5 ng/ml TGFb prior to sequential Wnt-3a treatment. B and C, Kinetic analysis of the effect of TGFb treatment on expression of mRNA for Axin-2 or Axin-2 protein, for shorter time periods (B) and longer time periods (C), determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and Western blot analysis. D, Axin-2 primary transcript expression, using primers spanning an intron-exon boundary, determined by qRT-PCR. E, Analysis of Axin-2 mRNA stability in healthy control and SSc fibroblasts following treatment with TGFb and 5 lg/ml of the transcriptional inhibitor actinomycin D, quantified by qRT-PCR and compared to control. Time points indicate half-life of mRNA for Axin-2. F, Effect of 48-hour 1 lM SD-208-mediated blockade of TGFb receptor type I on expression of mRNA for Axin-2 in healthy control and SSc fibroblasts, determined by qRT-PCR. All data are shown relative to healthy control fibroblasts with no stimulation (100%). G, Effect of knockdown of tristetraprolin 1 (TTP-1) by small interfering RNA (siRNA) specific for TTP-1 (siTTP) on TGFb-mediated expression of mRNA for Axin-2 and Dkk-1 in healthy control fibroblasts (with TGFb) and SSc fibroblasts, determined by qRT-PCR. H, Effect of TTP-1 knockdown by TTP-1-specific siRNA (siTTP-1) on TGFb-mediated expression of Axin-2, Dkk-1, and a-SMA protein in healthy control fibroblasts (with TGFb), quantified by Western blot analysis. Values are the mean AE SEM (n = 3-8 experiments). * = P = 0.05; ** = P < 0.01; **** = P < 0.001 by Mann-Whitney U test. SCR = scrambled (see Figure 1 for other definitions). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40437/abstract. contrast, TGFb treatment had a modest effect on expression of mRNA for Axin-1 and, unlike the case with Axin-2, protein expression remained unchanged (see Supplementary Figure 1C , http://onlinelibrary.wiley.com/doi/ 10.1002/art.40437/abstract).
To determine whether TGFb could regulate Axin-2 at the transcriptional level, expression of the Axin-2 primary transcript was evaluated. TGFb induced an increase in primary transcript expression at 10 minutes and 30 minutes by 166.9% (P < 0.01) and 199.6% (P < 0.05), respectively ( Figure 3D ). At time points ≥60 minutes, TGFb reduced the expression of the primary transcript to a maximum of 49.4% (P < 0.05) ( Figure 3D ). As reduction of primary transcript expression occurred at ≥60 minutes, actinomycin D was used to determine the posttranscriptional effects of TGFb on the mature Axin-2 transcript. In the presence of TGFb, the half-life of mRNA for Axin-2 in healthy control fibroblasts decreased from 129 minutes to 27 minutes over a time period of 30-210 minutes, which is equal to a 4.7-fold (P < 0.01) Figure 4 . Silencing of Axin-2 expression is sufficient to reproduce the canonical Wnt signaling amplitude observed in SSc and TGFb-primed fibroblasts. A, Healthy control fibroblasts were transfected with scrambled (SCR) small interfering RNA (siRNA) or Axin-2-specific siRNA (siAXIN2). Expression of Axin-2 mRNA at 24 hours and expression of Axin-2 protein at 48 and 72 hours were quantified by quantitative reverse transcriptase-polymerase chain reaction and Western blot analysis, respectively. B, Healthy control fibroblasts were transfected with the TOPflash reporter 24 hours prior to transfection with scrambled siRNA or Axin-2-specific siRNA for 48 hours. Subsequently, cells were either left untreated or were treated with Wnt-3a for a further 24 hours prior to determination of reporter activity. TOPflash activity of Wnt-3a-stimulated scrambled siRNA-transfected cells was set to 1. C, Healthy control fibroblasts were treated with 1 lM of Axin-stabilizing XAV-939 for 24 hours, and expression of Axin-2 was determined by Western blot analysis. D, One hour after XAV-939 treatment, XAV-939-mediated Axin-2 stability in the presence of TGFb for 24 hours was validated by Western blot analysis. E, Fibroblasts were transfected with the TOPflash reporter for 24 hours, and XAV-939 was added 1 hour prior to either no treatment or treatment with TGFb for 24 hours. Fibroblasts were then treated for a further 24 hours with Wnt-3a, and luciferase reporter activity was assayed. Values are the mean AE SEM (n = 4-5 experiments). * = P < 0.05; **** = P < 0.001 by Mann-Whitney U test. See Figure 1 for other definitions.
increase in the rate of mRNA decay ( Figure 3E ). Under the same experimental conditions, the basal half-life of mRNA for Axin-2 in SSc fibroblasts was 58 minutes compared to 129 minutes in healthy control fibroblasts (2.2-fold faster decay; P < 0.05), which was further reduced to 25 minutes by TGFb stimulation ( Figure 3E ).
To determine whether these effects were a direct consequence of TGFbR activation, SD-208 TbRI Kinase Inhibitor was used to selectively antagonize TGFb signaling. In healthy control fibroblasts, TGFb-mediated reduction of mRNA for Axin-2 by 64% (P < 0.01) was prevented in the presence of SD-208, as expected ( Figure 3F ). The same effects were observed at the protein level (see Supplementary Figure 2A , http://onlinelibrary.wiley.com/doi/10.1002/ art.40437/abstract) and on down-regulation of mRNA for Dkk-1 and up-regulation of mRNA for a-SMA, as expected (see Supplementary Figure 2B ). More interestingly, a similar pattern was also seen in SSc fibroblasts ( Figure 3F ). Although levels of mRNA for Axin-2 in SD-208-treated SSc fibroblasts were not fully restored to levels in untreated healthy control fibroblasts, we observed a 50% increase in basal levels of mRNA for Axin-2 (P < 0.05) (Figure 3F ), which confirms that endogenous activation of TGFbRI kinase is at least in part responsible for the decreased basal levels of mRNA for Axin-2 in SSc fibroblasts.
Bioinformatic analysis revealed the presence of several AU-rich elements (AREs) located in the 3 0 -untranslated region (3 0 -UTR) of the Axin-2 transcript (see Supplementary Figure 2C , http://onlinelibrary.wiley.com/ doi/10.1002/art.40437/abstract). Recruitment of TTP-1 to ARE-containing transcripts leads to destabilization and degradation (30) (31) (32) (33) (34) . Concordantly, siRNA-mediated silencing of mRNA for TTP-1 in SSc fibroblasts increased expression of mRNA for Axin-2 and Dkk-1 relative to nontargeting (scrambled) siRNA by 151% (P < 0.05) and 142% (P < 0.05), respectively, and in healthy control fibroblasts treated with TGFb by 162.1% (P < 0.01) and 161.5% (P < 0.01), respectively ( Figure 3G ). Consistent with these data, Axin-2 and Dkk-1 protein expression was substantially upregulated by TTP-1 knockdown in healthy control fibroblasts treated with TGFb at 48 and 72 hours ( Figure 3H ).
Axin-2 expression critically regulates canonical Wnt signaling hyperactivation in TGFb-primed fibroblasts. TGFb priming reproduced the increased canonical Wnt signaling response in healthy control fibroblasts at levels equivalent to those in SSc fibroblasts. Since SSc fibroblasts had a reduction in Axin-2, we sought to determine whether the TGFb-mediated down-regulation of Axin-2 was sufficient to explain this increased activation.
Small interfering RNA-mediated silencing of mRNA for Axin-2 reduced its expression to 50%, and similar results were observed at the protein level, at 48 and 72 hours, compared to expression in fibroblasts transfected with scrambled siRNA ( Figure 4A ). Wnt-3a stimulation of healthy control fibroblasts transfected with Axin-2 siRNA showed an increase in TOPflash activity, which was 5.8-fold higher than TOPflash activity in Wnt-3a-stimulated cells transfected with scrambled siRNA (P < 0.05) ( Figure 4B) .
Following a reciprocal approach, Axin-2 bioavailability was increased by treating fibroblasts with XAV-939, a small-molecule inhibitor known to stabilize Axin by inhibiting its proteasomal degradation (35) . As expected, TGFb-treated fibroblasts treated with XAV-939 stabilized Axin-2 in a dose-dependent manner and also prevented TGFb-induced down-regulation of Axin-2 following 48-hour stimulation (Figures 4C and D) . Subsequently, we determined the effects of Axin stabilization on canonical signaling activity. Healthy control fibroblasts treated with Wnt-3a for 24 hours were used as positive controls of TOPflash activity ( Figure 4E ). Cotreatment with incremental concentrations of XAV-939 led to a dose-dependent suppression of Wnt-3a-induced TOPflash activation ( Figure 4E ). Similarly, in TGFb-primed fibroblasts, the Wnt-3a-induced 2.1-fold hyperactivation of TOPflash activity was completely suppressed in the presence of XAV-939 ( Figure 4E ).
DISCUSSION
TGFb has an established role in the fibroblastmediated pathogenesis of tissue fibrosis. Recently, several studies have shown significantly increased Wnt signaling activation in fibroblasts resident in fibrotic tissues, suggesting that the Wnt pathway could be as important as that of TGFb in the pathogenic process (10, 11) . The current study has identified a new mechanism by which TGFb cross-talk mediates hyperactivation of the canonical Wnt/b-catenin signaling response in fibroblasts without inducing a direct stimulatory effect.
Although explanted SSc fibroblasts do not display an autonomous increase in canonical Wnt signaling activation, a significant increase in response to canonical agonist treatment is observed when compared to healthy control fibroblasts. This suggests that canonical signaling hyperactivation in vivo is likely to be influenced by the secretion of Wnt agonists from other cell types present in the local microenvironment. Several in vivo studies support the role of differential Wnt ligand expression in the increased activation of the canonical Wnt signaling pathway in SSc and models of experimental fibrosis (10, 11, 36) . The current study extends these previous observations and indicates the importance of TGFb-responsive Axin-2 expression in the regulation of canonical Wnt signaling pathway hyperactivation.
Consistently, SSc fibroblasts also display a decrease in the basal expression of Axin-2, a critical scaffold protein important in the formation and function of the b-catenin destruction complex (18, 19) . In support of the relationship between TGFb signaling and Axin-2 expression, TbRIIDk-fib-transgenic mice, which have constitutively active and fibroblast-specific TGFb signaling, showed reduced Axin-2 expression in both fibrotic skin and lung tissue. Indeed, suboptimal assembly of the b-catenin destruction complex, through down-regulation of the Axin-2 scaffold protein, could explain the increased nuclear b-catenin staining observed in tissue expression studies as well as the amplitude of canonical Wnt signaling evident in SSc fibroblasts (10, 11) . Complementary to this hypothesis, TGFb induced a quantitatively similar reduction in Axin-2 expression in healthy control fibroblasts and conferred the enhanced canonical Wnt signaling amplitude observed in SSc fibroblasts. Gene profiling of TGFb-responsive genes in dcSSc dermal fibroblasts, which are limited to an intrinsic SSc gene signature described by Milano et al, showed a significant downregulation of Axin-2 and Dkk-1, 2 important negative regulators of Wnt signaling, despite the overall absence of a distinct Wnt signaling profile (7, 36, 37) .
Taken together, these data suggest that a TGFbprimed microenvironment can lead to the increased canonical Wnt/b-catenin signaling in dermal fibroblasts observed during fibrosis, through its associated repression of key mediators regulating the Wnt signaling pathway. Interestingly, TGFb did not directly induce canonical Wnt activation in dermal fibroblasts, and therefore the increased canonical Wnt signaling response in vivo is likely to be through secretion of Wnt agonists by other cell types present in the local microenvironment rather than through an autocrine mechanism. These data offer a mechanistic explanation for both our observations on Axin-2 and the data already reported by Akhmetshina et al, which show a decrease in Dkk-1 expression following stimulation with TGFb (26) . In this sense, TGFbinduced degradation of mRNA for Axin-2 and Dkk-1 can work synergistically in priming and potentiating Wnt signaling acting at the extracellular level by reduction of a Wnt antagonist (reduction in Dkk-1) and at the intracellular level by decreased activity of GSK complex inhibition.
In this context, our observation of decreased expression of Axin-2 in TbRIIDk-fib-transgenic mice is rather indicative of a lack of direct Wnt activation in this model, and it suggests that the observed increase in Wnt signaling in scleroderma remains dependent on the presence of Wnt ligands. This is also supported by our in vitro data showing a lack of TOPflash activity in cells treated only with TGFb. Indeed, Wei et al have observed an increase in Wnt10a ligand in SSc skin and a TGFb-independent profibrotic signature in skin from transgenic mice with overexpression of Wnt-10a (38) . Further studies dissecting the functional effects of physiologic or aberrant Wnt signaling in this model are warranted to elucidate this cross-talk further.
Mechanistically, the TGFb-induced down-regulation of Axin-2 in dermal fibroblasts was mediated by an increase in the rate of decay of mRNA for Axin-2, while analysis of the primary transcript indicated involvement in transcriptional repression at later time points. Interestingly, TGFb-mediated repression of Axin-2 in chondrocytes was not similarly affected until 24 hours posttreatment; thus, the regulation of Axin-2 by TGFb appears to be context dependent (25) .
The degradation of the majority of eukaryotic mRNAs occurs through poly(A) tail shortening and is mediated by the recruitment of the RNA-degrading exosome complex (30) . TTP-1, a TGFb-responsive ARE-binding protein, can facilitate the recruitment of the exosome complex and enhance mRNA decay in transcripts containing 3 0 -UTR ARE motifs, including TNF, c-myc, and CCND1 (30) (31) (32) (33) (34) . Consistent with the presence of ARE motifs located within the 3 0 -UTR of the Axin-2 gene, silencing of TTP-1 expression led to a significant up-regulation of both Axin-2 mRNA and protein expression. Likewise, expression of the gene for Dkk-1, which also harbors 3 0 -UTR ARE motifs, was similarly increased. These data extend findings from a previous study linking canonical signaling activation to a reduction in a secreted Wnt signaling regulator, Dkk-1, driven by TGFb signaling in lung fibroblasts and the Ad-TbRI model of experimental fibrosis (39) . Taken together, these data suggest that ARE-mediated decay of mRNA for Axin-2 and Dkk-1, 2 regulators of canonical Wnt signaling, might be a common mechanism by which TGFb positively regulates the amplitude of canonical Wnt signaling and contributes to the pathogenic fibrotic response of fibroblasts.
We confirmed our hypothesis with gain-and lossof-function experiments, in which depletion of Axin-2 in healthy control fibroblasts increased canonical Wnt signaling and reproduced the SSc fibroblast phenotype. Reciprocally, inhibition of Axin protein degradation by XAV-939 treatment completely ablated the canonical Wnt signaling hyperactivation conferred by TGFb priming. In vivo, this has proved effective in protecting against experimental fibrosis (39) .
Overall, our study highlights the importance of TGFb cross-talk in regulating mediators of the canonical Wnt signaling pathway and shows that it is possible to reproduce the hyperresponsiveness to Wnt stimulation characteristic of SSc fibroblasts through depletion of Axin-2. This suggests that the increased canonical Wnt/ 940 GILLESPIE ET AL b-catenin signaling in fibroblasts, observed during fibrosis, is a consequence of a TGFb-primed microenvironment. This novel mechanism extends our understanding of the processes involved in Wnt/b-catenin-driven pathology and extends the rationale for developing TGFb-targeted treatment to the possibility of regulating the aberrant Wnt activation observed during fibrosis.
